HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DUALITYBIO-B

406.400

+3.6000.89%

Volume:917.50K

Turnover:380.22M

Market Cap:35.78B

PE:-2.83

High:433.000

Open:410.400

Low:405.000

Close:402.800

52wk High:433.800

52wk Low:165.500

Shares:88.04M

HK Float Shares:88.04M

Volume Ratio:0.98

T/O Rate:1.04%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-143.588

ROE:--

ROA:-6.51%

PB:11.23

PE(LYR):-2.83

PS:15.07

Loading ...

Overview Company News Filings

Haitong International: Maintains "Better Than Market" Rating for DUALITYBIO-B (09606), Raises Target Price to HK$464.2

Hong Kong Stock Alert | DUALITYBIO-B (09606) Surges Over 8% in Early Trading Following Official Inclusion in Hong Kong Stock Connect and Successful HER2 ADC Breast Cancer Phase III Study

HK Movers | Transthera-B, DualityBio-B Shares Surged About 16% After Being Added to the List of Securities for Southbound Trading

Tiger Newspress

Duality Biotherapeutics to Join Hang Seng Index

MT Newswires Live

BUZZ-Duality Biotherapeutics hits record high on inclusion in Stock Connect programme

Hong Kong Stock Movement | DUALITYBIO-B (09606) Opens Up Over 4% on Inclusion in Hang Seng Composite Index and Breast Cancer Drug Phase III Clinical Success

DUALITYBIO-B (09606) Included in Hang Seng Composite Index Constituent Stocks

BioNTech SE (BNTX.US) Experimental Breast Cancer Drug Achieves Success in Trial

Duality Biotherapeutics Inc. Announces Successful Phase III Trial Results for DB-1303/BNT323 in HER2-Positive Breast Cancer Patients

DUALITYBIO-B (09606): Phase III Clinical Trial of DB-1303/BNT323 for HER2-Positive Unresectable or Metastatic Breast Cancer Patients Achieves Primary Endpoint

BioNTech, Duality score initial trial win with breast cancer precision drug

BioNTech - Dualitybio to Discuss Next Steps With China's Center for Drug Evaluation on Submission of Biologics License Application

THOMSON REUTERS

BioNTech - Additional Global Phase 3 Dynasty-Breast02 Trial of Trastuzumab Pamirtecan Ongoing and on Track

THOMSON REUTERS

BioNTech and Dualitybio Announce Phase 3 Trial of ADC Candidate Bnt323/Db-1303 (Trastuzumab Pamirtecan) Met Primary Endpoint

THOMSON REUTERS

Hong Kong Stock Alert | DUALITYBIO-B (09606) Surges Over 5% in Early Trading with Strong H1 Revenue Growth, Company's Potential Transaction Value Exceeds $6 Billion

BRIEF-Duality Biotherapeutics Posts HY Adjusted Profit RMB145.9 Million

DUALITYBIO-B (09606) Reports Adjusted Profit of Approximately 146 Million Yuan in First Half, Up 14.2% Year-over-Year

Duality Biotherapeutics Inc - Hy Revenue RMB1.23 Bln

THOMSON REUTERS

BRIEF-Duality Biotherapeutics Says DB-1310 Granted FDA Fast Track Designation

Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/09606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"DUALITYBIO-B","latestPrice":406.4,"timestamp":1757405293005,"preClose":402.8,"halted":0,"volume":917500,"delay":0,"floatShares":88036299,"shares":88036299,"eps":-143.58362462741312,"marketStatus":"Not Yet Opened","change":3.6,"latestTime":"09-09 16:08:13","open":410.4,"high":433,"low":405,"amount":380220393,"amplitude":0.069513,"askPrice":406.8,"askSize":200,"bidPrice":406.4,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":-124.56136500773286,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":402.8,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"volumeRatio":0.984412,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":88036299,"roa":"-6.51%","roe":"--","lyrEps":-143.587564,"volumeRatio":0.984412,"shares":88036299,"dividePrice":0,"high":433,"amplitude":0.069513,"preClose":402.8,"low":405,"week52Low":165.5,"pbRate":"11.23","psRate":"15.07","week52High":433.8,"institutionHeld":0,"latestPrice":406.4,"committee":0.8,"eps":-143.5875530656366,"divideRate":0,"volume":917500,"delay":0,"ttmEps":-124.56477299822436,"open":410.4,"prevYearClose":94.6,"prevWeekClose":363.2,"prevMonthClose":315.6,"prevQuarterClose":236.6,"fiveDayClose":367,"twentyDayClose":351.8,"sixtyDayClose":261},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1749657600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2025-09-08","current":-11.460474,"percent":0.92,"low":-29.984477,"twenty":-25.49466,"median":-18.863356,"eighty":-15.219573,"high":-7.368305,"avg":-19.594568,"sd":5.500695,"marketCap":35461007139},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-08","current":-11.460474,"twenty":-25.49466,"median":-18.863356,"eighty":-15.219573,"marketCap":35461007139}],"updateTime":1757416495006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121498946","title":"Haitong International: Maintains \"Better Than Market\" Rating for DUALITYBIO-B (09606), Raises Target Price to HK$464.2","url":"https://stock-news.laohu8.com/highlight/detail?id=1121498946","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121498946?lang=en_us&edition=fundamental","pubTime":"2025-09-09 17:00","pubTimestamp":1757408439,"startTime":"0","endTime":"0","summary":"Haitong International released a research report stating that based on DUALITYBIO-B's (09606) H1 2025 revenue performance and clinical pipeline progress, the firm has raised its projection for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000500386.USD","HK0000252152.HKD","LU2543165471.USD","09606"],"gpt_icon":0},{"id":"1185232276","title":"Hong Kong Stock Alert | DUALITYBIO-B (09606) Surges Over 8% in Early Trading Following Official Inclusion in Hong Kong Stock Connect and Successful HER2 ADC Breast Cancer Phase III Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1185232276","media":"Stock News","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185232276?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:12","pubTimestamp":1757383945,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) surged over 8% in early trading. As of press time, the stock was up 3.97% to HK$418.8, with a trading volume of HK$133 million. On the news front, starting September 8th,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","BK4231","III","HK0000500386.USD","HK0000252152.HKD","ADC","HSCEI","LU2543165471.USD","09606","07226","BK4134","YANG","BK4614","BK4080"],"gpt_icon":1},{"id":"1174923850","title":"HK Movers | Transthera-B, DualityBio-B Shares Surged About 16% After Being Added to the List of Securities for Southbound Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174923850","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174923850?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:51","pubTimestamp":1757299883,"startTime":"0","endTime":"0","summary":"Transthera-B, DualityBio-B shares surged about 16% after being added to the list of securities for Southbound Trading.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8897b9b2c5acf19f1f0d138877ea54a6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","02617"],"gpt_icon":0},{"id":"2565579998","title":"Duality Biotherapeutics to Join Hang Seng Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2565579998","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565579998?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:01","pubTimestamp":1757296888,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics  said it was due to join the Hang Seng Index on Monday, Sept. 8, according to a Hong Kong bourse filing Sunday.Shares of the biopharmaceutical firm gained nearly 11% in morning trade Monday.The company's stock would also be eligible for inclusion to the southbound trading link of the Shanghai bourse's Shanghai-Hong Kong Stock Connect the same day.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8897b9b2c5acf19f1f0d138877ea54a6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09606","LU2543165471.USD","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"2565579312","title":"BUZZ-Duality Biotherapeutics hits record high on inclusion in Stock Connect programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2565579312","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565579312?lang=en_us&edition=fundamental","pubTime":"2025-09-08 09:57","pubTimestamp":1757296679,"startTime":"0","endTime":"0","summary":"BUZZ-Duality Biotherapeutics hits record high on inclusion in Stock Connect programme** Shares of Duality Biotherapeutics Inc 9606.HK jump 14.3% to HK$415, their highest point and the biggest intraday pct gain since debut on April 15** The biopharmaceuticals group says it will be included as a constituent stock of the Hang Seng Composite Index and in the list of eligible shares of the Southbound Trading Link of the Shanghai-Hong Kong Stock Connect effective September 8** Hang Seng Biotech Index .HSHKBIO rises 1.6%, benchmark Hang Seng Index .HSI adds 0.3%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8897b9b2c5acf19f1f0d138877ea54a6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL2N3UV01J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09606","HK0000500386.USD","LU2543165471.USD","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"1180107963","title":"Hong Kong Stock Movement | DUALITYBIO-B (09606) Opens Up Over 4% on Inclusion in Hang Seng Composite Index and Breast Cancer Drug Phase III Clinical Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1180107963","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180107963?lang=en_us&edition=fundamental","pubTime":"2025-09-08 09:30","pubTimestamp":1757295020,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) opened up over 4%. As of press time, the stock rose 4.63% to HK$380, with a turnover of HK$7.506 million. On the news front, DUALITYBIO-B announced that starting from September...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8897b9b2c5acf19f1f0d138877ea54a6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","HK0000252152.HKD","HSCI","BK1161","09606","HK0000500386.USD","HK0000252160.HKD","III","LU2543165471.USD"],"gpt_icon":0},{"id":"1114943196","title":"DUALITYBIO-B (09606) Included in Hang Seng Composite Index Constituent Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1114943196","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114943196?lang=en_us&edition=fundamental","pubTime":"2025-09-07 19:04","pubTimestamp":1757243058,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) announced that effective September 8, 2025, the company's shares will (i) be included as constituent stocks of the Hang Seng Composite Index by Hang Seng Indexes Company Limited...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2543165471.USD","HK0000500386.USD","HK0000252160.HKD","09606","HSCI","HK0000252152.HKD"],"gpt_icon":0},{"id":"1144495317","title":"BioNTech SE (BNTX.US) Experimental Breast Cancer Drug Achieves Success in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1144495317","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144495317?lang=en_us&edition=fundamental","pubTime":"2025-09-05 18:50","pubTimestamp":1757069422,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX.US) announced that an experimental drug developed in collaboration with DUALITYBIO-B (09606) has achieved success in breast cancer research, marking the first successful outcome of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK4535","BK4568","BK4588","BK4548","BK4551","BK4585","HK0000500386.USD","BNTX","09606","BK4139","BK1161","LU2543165471.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2565555246","title":"Duality Biotherapeutics Inc. Announces Successful Phase III Trial Results for DB-1303/BNT323 in HER2-Positive Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2565555246","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565555246?lang=en_us&edition=fundamental","pubTime":"2025-09-05 17:11","pubTimestamp":1757063516,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc. Announces Successful Phase III Trial Results for DB-1303/BNT323 in HER2-Positive Breast Cancer Patients. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL3P9VhQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","BK1161","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","LU2543165471.USD"],"gpt_icon":0},{"id":"1111130751","title":"DUALITYBIO-B (09606): Phase III Clinical Trial of DB-1303/BNT323 for HER2-Positive Unresectable or Metastatic Breast Cancer Patients Achieves Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1111130751","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111130751?lang=en_us&edition=fundamental","pubTime":"2025-09-05 17:10","pubTimestamp":1757063427,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) announced that following evaluation by the Independent Data Monitoring Committee (IDMC), the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4118","BK4566","BK4585","LU2543165471.USD","HK0000500386.USD","DB","III","HK0000252152.HKD","BK4588","09606","BK1161","BK4552","BK4134","HK0000252160.HKD"],"gpt_icon":0},{"id":"2565555241","title":"BioNTech, Duality score initial trial win with breast cancer precision drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2565555241","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565555241?lang=en_us&edition=fundamental","pubTime":"2025-09-05 17:10","pubTimestamp":1757063418,"startTime":"0","endTime":"0","summary":"BioNTech, Duality score initial trial win with breast cancer precision drugFRANKFURT Sept 5  - BioNTech 22UAy.DE and its partner Duality Biologics 9606.HK said on Friday that a late-stage trial testing their precision drug against a certain type of breast cancer reached its main goal of slowing down disease progression.For COVID-19 vaccine maker BioNTech, the news marks the first success in a cancer trial that could potentially lead to market approval amid a renewed focus on its traditional roots in oncology. In a joint statement, the partners said that a Phase 3 trial testing experimental drug BNT323 in China in comparison with Roche's ROG.S Kadcyla in certain cases of breast cancer met the primary endpoint of progression-free survival at a pre-specified interim analysis.  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nS8N3TJ02A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","BK1161","HK0000500386.USD","HK0000252152.HKD","09606","HK0000252160.HKD"],"gpt_icon":0},{"id":"2565955526","title":"BioNTech - Dualitybio to Discuss Next Steps With China's Center for Drug Evaluation on Submission of Biologics License Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2565955526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565955526?lang=en_us&edition=fundamental","pubTime":"2025-09-05 17:10","pubTimestamp":1757063414,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nS8N3TJ02A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09606","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","BK1161","LU2543165471.USD"],"gpt_icon":0},{"id":"2565555261","title":"BioNTech - Additional Global Phase 3 Dynasty-Breast02 Trial of Trastuzumab Pamirtecan Ongoing and on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2565555261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565555261?lang=en_us&edition=fundamental","pubTime":"2025-09-05 17:10","pubTimestamp":1757063414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nS8N3TJ02A:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","BK1161","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","09606"],"gpt_icon":0},{"id":"2565266555","title":"BioNTech and Dualitybio Announce Phase 3 Trial of ADC Candidate Bnt323/Db-1303 (Trastuzumab Pamirtecan) Met Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2565266555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565266555?lang=en_us&edition=fundamental","pubTime":"2025-09-05 17:10","pubTimestamp":1757063414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nS8N3TJ02A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09606","HK0000500386.USD","HK0000252152.HKD","LU2543165471.USD","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"1140751318","title":"Hong Kong Stock Alert | DUALITYBIO-B (09606) Surges Over 5% in Early Trading with Strong H1 Revenue Growth, Company's Potential Transaction Value Exceeds $6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140751318","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140751318?lang=en_us&edition=fundamental","pubTime":"2025-09-02 11:52","pubTimestamp":1756785139,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) surged over 5% in early trading. As of press time, the stock was up 3.67% to HK$362, with trading volume reaching HK$104 million. On the news front, DUALITYBIO-B announced its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","BK1161","LU2543165471.USD"],"gpt_icon":0},{"id":"2562782775","title":"BRIEF-Duality Biotherapeutics Posts HY Adjusted Profit RMB145.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562782775","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562782775?lang=en_us&edition=fundamental","pubTime":"2025-08-26 18:23","pubTimestamp":1756203811,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics Posts HY Adjusted Profit RMB145.9 MillionAug 26 (Reuters) - Duality Biotherapeutics Inc 9606.HK:HY  ADJUSTED PROFIT  RMB145.9 MILLIONHY REVENUE RMB1.23 BILLIONFurther company coverage: 9606.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UI0BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252160.HKD","LU2543165471.USD","HK0000252152.HKD","BK1161","09606"],"gpt_icon":0},{"id":"1185563951","title":"DUALITYBIO-B (09606) Reports Adjusted Profit of Approximately 146 Million Yuan in First Half, Up 14.2% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1185563951","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185563951?lang=en_us&edition=fundamental","pubTime":"2025-08-26 17:44","pubTimestamp":1756201477,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) announced its interim results for 2025, reporting revenue of approximately 1.229 billion yuan, representing a year-over-year increase of 22.9%. Gross profit reached approximately...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","LU2543165471.USD","BK1161","09606","HK0000252160.HKD"],"gpt_icon":0},{"id":"2562448781","title":"Duality Biotherapeutics Inc - Hy Revenue RMB1.23 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562448781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562448781?lang=en_us&edition=fundamental","pubTime":"2025-08-26 17:33","pubTimestamp":1756200790,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UI0BQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","BK1161","HK0000252160.HKD","HK0000500386.USD","09606","HK0000252152.HKD"],"gpt_icon":0},{"id":"2553400291","title":"BRIEF-Duality Biotherapeutics Says DB-1310 Granted FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2553400291","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553400291?lang=en_us&edition=fundamental","pubTime":"2025-07-22 09:28","pubTimestamp":1753147715,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics Says DB-1310 Granted FDA Fast Track DesignationJuly 22 (Reuters) - Duality Biotherapeutics Inc 9606.HK:DB-1310 GRANTED FDA FAST TRACK DESIGNATIONFurther company coverage: 9606.HK ((Reuters.Briefs@thomsonreuters.com))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nFWN3TI19V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2553640410","title":"Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2553640410","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553640410?lang=en_us&edition=fundamental","pubTime":"2025-07-22 06:25","pubTimestamp":1753136706,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc., a prominent player in the global ADC landscape, has announced that its key product, DB-1310, has been granted Fast Track Designation by the U.S. Food and Drug Administration . This designation is intended to expedite the development and review process for DB-1310, an antibody-drug conjugate targeting human epidermal growth factor receptor 3 . The drug is being developed for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer  with specific genetic mutations and disease progression after prior therapies. The encouraging efficacy and manageable safety of DB-1310 were demonstrated in clinical trials, marking a significant step forward for Duality Biotherapeutics in bringing innovative cancer treatments to market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL1rxbKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09606"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}]}}